BYLieve study results Alpelisib and endocrine therapy in patients with PIK3CAmutatedHR HER2 advanced breast cancer

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

13:15 EDT 12 Jun 2019 | ecancermedicalscience

Prof Hope Rugo speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the BYLieve study. She describes the aim and methodology of the study, which was to assess the efficacy and toxicity of...

More From BioPortfolio on "BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer"